For GB Healthcare Professionals only .
HELP PROTECT YOUR 65 YRS + PATIENTS FROM FLU adjuvanted QUADRIVALENT
INFLUENZA VACCINE
( surface antigen , inactivated ) Seqirus aQIV is licensed for prophylaxis of influenza in adults aged 65 years and over .
RISK-FREE ORDERING *
EARLY DELIVERY
Contact us now to secure your aQIV order for the 2022 / 23 season .
You can phone us on 0345 0093 804 or email flu . salesuk @ seqirus . com
* Option to cancel all or part of your Seqirus flu vaccine ( s ) order if aQIV is not an NHS recommended and reimbursed option for 2022 / 23 .
Date of preparation November 2021 . Job code GBR-AQIV-21-0014 .
PRESCRIBING INFORMATION
Adjuvanted quadrivalent influenza vaccine ( surface antigen , inactivated ) Seqirus ,
suspension for injection in pre-filled syringe . Presentation : Each 0.5 ml dose of adjuvanted quadrivalent influenza vaccine ( aQIV ) contains 15 micrograms of each of the four strains that comply with the World Health Organization quadrivalent vaccine recommendations ( Northern Hemisphere ), with adjuvant MF59C . 1 ( 9.75 mg squalene , 1.175 mg polysorbate 80 , 1.175 mg sorbitan trioleate , 0.66 mg sodium citrate , 0.04 mg citric acid ). Indications : Prophylaxis of influenza in the elderly ( 65 years of age and older ). Dosage and Administration : A single 0.5 ml dose by intramuscular injection only ( preferred site is the deltoid muscle of the upper arm ). Contraindications : Hypersensitivity to the active substances , components of the adjuvant , excipients ( sodium chloride , potassium chloride , potassium dihydrogen phosphate , disodium phosphate dihydrate , magnesium chloride hexahydrate , calcium chloride dihydrate ), or to possible trace residues ( ovalbumin , kanamycin , neomycin sulphate , formaldehyde , cetyltrimethylammonium bromide , hydrocortisone ). A severe allergic reaction ( e . g . anaphylaxis ) to previous influenza vaccination . Warnings and Precautions : In order to improve the traceability of biological medicinal products , the name and the batch number of the administered product should be clearly recorded . Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine . Do not inject intravenously , subcutaneously or intradermally . aQIV must not be mixed with other vaccines in the same syringe . Postpone vaccination in patients with acute febrile illness until fever is resolved . Caution when administering to individuals with thrombocytopenia or bleeding disorder since bleeding may occur following intramuscular administration . Syncope ( fainting ) can occur following , or even before , any vaccination as a psychogenic response to the needle injection . This can be accompanied by several neurological signs such as transient visual disturbance , paraesthesia and tonicclonic limb movements during recovery . Ensure procedures are in place to avoid injury from faints . Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient to prevent influenza . A protective immune response may not be elicited in all vaccine recipients . Interactions : No clinical data on concomitant administration with other vaccines are available . If aQIV is to be
used at the same time as another vaccine , it should be administered at separate sites and preferably on different limbs . Adverse reactions may be intensified by any co-administration . Pregnancy and Lactation : This vaccine is for use in elderly adults 65 years and older . It is not to be used in women who are , or may be , pregnant or breast-feeding . Effects on Ability to Drive and Use Machines : No or negligible influence on the ability to drive and use machines . Side Effects : The most common reactions ( ≥1 / 10 ) are headache , injection-site pain , and fatigue . Commonly reported reactions ( ≥1 / 100 to < 1 / 10 ) are loss of appetite , nausea , diarrhoea , myalgia , arthralgia , ecchymosis , chills , erythema , induration , and influenza-like illness . Uncommon reactions ( ≥1 / 1000 to < 1 / 100 ) include vomiting and fever ( ≥38 ° C ). No post-marketing data is currently available for aQIV , however the post-marketing experience with Fluad ( trivalent formulation ) is relevant to aQIV as both vaccines are manufactured using the same process and have overlapping compositions . Adverse reactions reported from post-marketing surveillance with Fluad include thrombocytopenia , lymphadenopathy , extensive swelling of injected limb lasting more than one week , injection-site cellulitis-like reaction , allergic reactions including anaphylactic shock ( in rare cases ), anaphylaxis , angioedema , muscular weakness , nervous system disorders ( encephalomyelitis , Guillain- Barré syndrome , convulsions , neuritis , neuralgia , paraesthesia ), generalised skin reactions ( erythema multiforme , urticaria , pruritus or non-specific rash ), vasculitis that may be associated with transient renal involvement . Overdose : Overdose is unlikely to have any untoward effect .
Legal Category : POM . Package Quantities : Packs of 1 or 10 pre-filled syringes . Marketing Authorisation Number : PLGB 47991 / 0007 . Basic NHS Cost : £ 13.50 per 0.5 ml pre-filled syringe , £ 135.00 per 10 pack . Marketing Authorisation Holder : Seqirus UK Ltd ., Point , 29 Market Street , Maidenhead SL6 8AA , United Kingdom .
For full prescribing information and details of other side effects , please see the Summary of Product Characteristics at www . medicines . org . uk / emc .
GBR-AQIV-21-0001 Date of preparation : September 2021
Adverse events should be reported . Reporting forms and information can be found at www . mhra . gov . uk / yellowcard . Adverse events relating to Seqirus products should also be reported to Seqirus UK Limited on 01748 828816 .